

PRODUCT INFORMATION

Common Name	MOR208, XmAb5574, XmAb®5574, MOR-00208, MOR-208, XENP-5574, XMP-5574, XmAb-5574, Xmab-CD19, Xmab5574, tafasitamab-cxix
Conjugate	Unconjugated
Synonyms	CD19,B4,CVID3,MGC12802
Applications	ELISA, Flow Cyt
Endotoxin	Less than 1.0 EU/μg by the LAL method. For <1 EU/mg requirements, please contact us for customization.
Recommended Dilutions	ELISA 1:5000-10000, Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
IgG type	Human IgG1-G2 - kappa
Reactivity	Human
Target	CD19
Uniprot ID	P15391
Description	Anti-CD19(tafasitamab biosimilar) mAb
Delivery	In Stock
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized antibodies are shipped at ambient temperature.
Sterility	Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μm) prior to use.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only



Anti-CD19(tafasitamab biosimilar) mAb ELISA

0.2 μ g of Human CD19 (M75I,L82V,F83L), hFc tagged protein per well




Figure 1. ELISA plate pre-coated by 2 μ g/mL (100 μ L/well) Human CD19(M75I,L82V,F83L), hFc Tag (PME101557) can bind Anti-CD19(tafasitamab biosimilar) mAb (BME100683) in a linear range of 3.2-80 ng/mL.




Figure 2. Flow cytometry analysis with 0.5 μ g/ml Anti-CD19(tafasitamab biosimilar) mAb (BME100683) on HEK293 cells transfected with human CD19 (Blue histogram) or HEK293 transfected with irrelevant protein (Red histogram).

